Antibrush Border Antibody Disease: A Case Series

IF 3.2 Q1 UROLOGY & NEPHROLOGY
Michelle Pengshung , Vivek Charu , Megan L. Troxell , Shreeram Akilesh , Kelly D. Smith , J. Ashley Jefferson
{"title":"Antibrush Border Antibody Disease: A Case Series","authors":"Michelle Pengshung ,&nbsp;Vivek Charu ,&nbsp;Megan L. Troxell ,&nbsp;Shreeram Akilesh ,&nbsp;Kelly D. Smith ,&nbsp;J. Ashley Jefferson","doi":"10.1016/j.xkme.2024.100841","DOIUrl":null,"url":null,"abstract":"<div><p>Antibrush border antibody (ABBA) disease is a rare cause of kidney disease characterized by progressive renal tubular injury associated with immune complex deposition along the basement membranes of the proximal tubule and circulating autoantibodies to brush border antigens. Several antigens have been identified as targets of autoantibodies in this disease, including low-density lipoprotein receptor related protein 2 (LRP2), cubilin, and amnionless proteins. We present 9 patients from 2 academic medical centers and describe the clinicopathologic characteristics and outcome data. All patients presented with acute kidney injury and proteinuria. Pathology confirmed immune complex deposition along proximal tubular basement membranes in all patients, but the majority (6/8) also showed segmental glomerular subepithelial immune complexes. Two of 3 patients treated with rituximab demonstrated stabilization of kidney function; 1 of these patients had mantle cell lymphoma. One patient with lung cancer showed stabilization of disease after treatment of the malignancy. The remaining patients progressed to end-stage kidney disease with either conservative therapy (3 patients) or immunosuppression with glucocorticoids (2 patients). This series highlights the poor prognosis of ABBA disease, but a potential benefit of anti-B cell therapy or treatment of an underlying malignancy in some cases.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524000529/pdfft?md5=2ef0e5fa2d5c6c5c74deccdb243d9b86&pid=1-s2.0-S2590059524000529-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059524000529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Antibrush border antibody (ABBA) disease is a rare cause of kidney disease characterized by progressive renal tubular injury associated with immune complex deposition along the basement membranes of the proximal tubule and circulating autoantibodies to brush border antigens. Several antigens have been identified as targets of autoantibodies in this disease, including low-density lipoprotein receptor related protein 2 (LRP2), cubilin, and amnionless proteins. We present 9 patients from 2 academic medical centers and describe the clinicopathologic characteristics and outcome data. All patients presented with acute kidney injury and proteinuria. Pathology confirmed immune complex deposition along proximal tubular basement membranes in all patients, but the majority (6/8) also showed segmental glomerular subepithelial immune complexes. Two of 3 patients treated with rituximab demonstrated stabilization of kidney function; 1 of these patients had mantle cell lymphoma. One patient with lung cancer showed stabilization of disease after treatment of the malignancy. The remaining patients progressed to end-stage kidney disease with either conservative therapy (3 patients) or immunosuppression with glucocorticoids (2 patients). This series highlights the poor prognosis of ABBA disease, but a potential benefit of anti-B cell therapy or treatment of an underlying malignancy in some cases.

抗刷毛边界抗体病:病例系列
刷状缘抗体病(ABBA)是一种罕见的肾脏疾病,其特点是肾小管进行性损伤,与沿近端肾小管基底膜的免疫复合物沉积和针对刷状缘抗原的循环自身抗体有关。目前已确定几种抗原是该病自身抗体的靶点,包括低密度脂蛋白受体相关蛋白2(LRP2)、立方体蛋白和无羊膜蛋白。我们介绍了来自两个学术医疗中心的9名患者,并描述了他们的临床病理特征和结果数据。所有患者均出现急性肾损伤和蛋白尿。病理证实,所有患者的免疫复合物均沿近端肾小管基底膜沉积,但大多数患者(6/8)还出现了节段性肾小球上皮下免疫复合物。在接受利妥昔单抗治疗的 3 名患者中,有 2 名患者的肾功能趋于稳定;其中 1 名患者患有套细胞淋巴瘤。一名肺癌患者在接受恶性肿瘤治疗后病情趋于稳定。其余患者在接受保守治疗(3 例)或糖皮质激素免疫抑制治疗(2 例)后,病情发展为终末期肾病。这一系列病例突出表明 ABBA 病预后较差,但在某些病例中,抗 B 细胞治疗或潜在恶性肿瘤治疗可能会带来益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信